Order form



This new **updated** and **enriched** edition offers you in a clear, precise and concise format:

- 1. A review of the worldwide pharma market
- 2. A presentation of the French healthcare system and of the latest measures introduced by health authorities
- 3. An analysis of the position of the various stakeholders
- 4. An assessment of their behavioral trends by 2029
- 5. An **estimate** of the **impact** of this evolution on the **market** and on **pharma companies' strategies by 2029**





Order form The French Pharma Market 2024 – 2029 Strategic Implications for Pharma Companies

- I wish to purchase a PowerPoint version of this report (434 slides) in English at a price of € 10,000 (excl. taxes)*, including:
 - A free update of the report until September 30, 2025
 - An e-workshop meeting of ~2 hours (possibility of face-to-face workshop in Paris area)
- I pay Smart Pharma Consulting by bank transfer to: Société Générale – IBAN : FR76 3000 3027 4100 0200 1061 171 SWIFT: SOGEFRPP

Fill out and send your order form to: Email : *jmpeny@smart-pharma.com* – Tel. : +33 6 11 96 33 78 Smart Pharma Consulting - 1, rue Houdart de Lamotte - 75015 Paris – France

The report will be sent to you with an invoice by e-mail to:

Last name:	First name:
Function:	Company:
Address:	Zip code:
City:	Country:
E-mail:	Phone:


* Unlimited use within the different legal entities of the group having purchased this report. It is permitted to save this report only on computers and hard drives belonging to the legal entity. This report can be disseminated to the legal entity employees only



The French Pharma Market 2024 – 2029 Strategic Implications for Pharma Companies

"A rigorous analysis of the facts to support the strategic thinking of pharmaceutical companies"

434 illustrated slides



Contents

Introduction

- 1. Worldwide market overview
 - 1.1. Healthcare expenditure
 - 1.2. Pharma market attractiveness 1.3. Pharma R&D trends
- 1.4. Pharma companies' strategies
- 1.5. Synthesis

- 2. French healthcare system
 - 2.1. Key stakeholders
 - 2.2. Policy makers: Government ARS ANSM HAS CEPS
 - 2.3. Payers
 - 2.4. Providers: Territorial organization HCPs Healthcare facilities Drug suppliers – Consumers / Patients
 - 2.5. Expenditure & regulation
 - 2.6. Synthesis

4.4. Physicians

- 3. French pharma market
 - 3.1. Structure and dynamics
 - 3.2. Orphan drugs segment
 - 3.3. Generics segment 3.4. Biosimilars segment

- 3.5. OTC segment 3.6. Market forecasts
- 3.7. Synthesis
- 4. Strategic priorities for pharma companies
 - 4.1. Methodology4.2. Stakeholders mapping4.3. Policy makers & Payers

- 4.5. Pharmacists
- 4.6. Patients & PAGs
- 4.7. Pharma competitors

Executive Summary: Strategic implications for pharma companies Glossary